Search results
Results from the WOW.Com Content Network
Learn what a PSA test is, plus the limitations and potential harms of the test when used to screen for prostate cancer.
Prostate cancer screening may help detect prostate cancer, but remains controversial as it has not been shown to reduce deaths from prostate cancer. Learn more about prostate cancer screening, including the potential benefits and harms, in this expert-reviewed summary.
Prostate cancer is the most common cancer among men in the United States. Prostate cancer usually grows very slowly, and finding and treating it before symptoms occur may not improve men’s health. Start here to find information on prostate cancer treatment, research, causes and prevention, screening, and statistics.
Learn about prostate changes and symptoms that are not cancer, plus risk factors and treatment for prostatitis, enlarged prostate (BPH), prostate cancer. Talk with your doctor about prostate cancer screening tests (DRE, PSA).
Researchers funded by NCI have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy after an elevated prostate-specific antigen (PSA) test from those who can wait.
National guidelines recommend discussing prostate cancer screening with prostate-specific antigen (PSA) and digital rectal exam between the ages of 45 and 75 years for individuals at average risk for prostate cancer. In contrast, prostate cancer screening is recommended to start at age 40 years for individuals in these high-risk groups:
Tests that examine the prostate and blood are used to diagnose prostate cancer. A biopsy is done to diagnose prostate cancer and find out the grade of the cancer (Gleason score). Certain factors affect prognosis (chance of recovery) and treatment options.
Prostate cancer screening with the prostate-specific antigen (PSA) test or digital rectal exams has not been shown to reduce prostate cancer deaths. Get detailed information about prostate cancer screening, including potential benefits and harms, in this summary for clinicians.
A large study has confirmed that a genetic test can correctly predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. The test could help people with prostate cancer and their doctors choose the most appropriate treatment, the researchers concluded.
In a new study, a genomic test appeared to be better at finding aggressive prostate cancer than conventional tests. The genomic test, called Decipher, looks at the activity of 22 genes and has been shown to predict the risk that a prostate tumor will spread (metastasize).